NEW YORK (GenomeWeb) – Hospital Corporation of America (HCA) today announced that it will acquire personalized medicine software developer Genospace.
Under the terms of the deal, Genospace will merge with HCA's Sarah Cannon cancer institute as a wholly-owned subsidiary. Financial and other terms of the agreement were not disclosed.
"As genomic information advances, it is crucial that oncologists and researchers have rapid access to an efficient and nimble technology solution for interpreting molecular data and guiding clinical decision making," Sarah Cannon Chief Medical Officer Howard Burris III said in a statement.
Genospace is developing a cloud-based platform that includes applications for data analysis, clinical trial matching, patient and physician portals, and hosting for disease-specific online communities. Sarah Cannon said it will incorporate the genomics data technology into its oncology programs in the US and the UK.
Sarah Cannon expects to complete the deal in the first quarter of fiscal year 2017. Genospace will remain headquartered in Cambridge, Massachusetts.